Federation Des Caisses Desjardins Du Quebec Alkermes Plc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Aug 30, 2024	SELL	$16.16 - $20.66 $775 - $991	-48 Closed	0 $0
Q1 2020 Aug 30, 2024	SELL	$13.06 - $21.24 $41,334 - $67,224	-3,165 Reduced 98.51%	48 $692,000
Q4 2019 Aug 30, 2024	BUY	$17.29 - $21.74 $54,722 - $68,807	3,165 Added 6593.75%	3,213 $65.5 Million
Q4 2018 Aug 30, 2024	BUY	$27.94 - $44.61 $1,341 - $2,141	48 New	48 $1.42 Million
Q1 2017 Aug 30, 2024	BUY	N/A	48	48 $2.81 Million

Others Institutions Holding ALKS

# of Institutions

361

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$838 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$546 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$374 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$364 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$264 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account